All News

Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/MQmkUe4Yey https://t.co/FSfrznoeBe

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/MQmkUe4Yey https://t.co/FSfrznoeBe

Links:

Dr. John Cush RheumNow ( View Tweet)
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease. https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish study of 4033 incident RA vs 6485 controls - Exposure to occupational inhalable increased risk ACPA+ RA (OR 1.25). Occupational inhalable agents plus smoking and shared epitope markedly elevated risk (OR 18.22) esp in ACPA+RA https://t.co/4lKLEhkURm https://t.co/HFhz8lMR10

Links:

Dr. John Cush RheumNow ( View Tweet)
LiveVote.jpg

Substandard Therapy in Rheumatoid Arthritis

d Medpage Today

Clinicians could improve outcomes in their patients with rheumatoid arthritis (RA) by paying attention to certain markers of care quality, such as early referral to certified rheumatologists and prescribing standard drugs for RA, new research suggested.

Read Article
Small, open label study of 43 RA pts Rx w/ csDMARDs randomized to denosumab or PBO x 24 weeks. Erosions of MCP 2,3 assessed by HR-pQCT shows no significant differences in erosions or safety signals at 6 mos between groups. https://t.co/AuysVPFD4S https://t.co/yQ4R41hSMi

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study in RA shows Red cell distribution width (RDW) & absolute lymphocyte count (ALC) predict 10 yr mortality (P < 0.001); highest with both high RDW and low ALC. Data developed on 327 VA RA pts & validated on national cohort (13,914) https://t.co/aBGECUfKGH https://t.co/qkvv1PmvSB

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/h6zpTOIuyu https://t.co/Gy3Eaqz8sM

Links:

Dr. John Cush RheumNow ( View Tweet)
Steroids in RA: Friend or foe (or both)? Abstract 2000 presents longer-term follow-up data from the recently published GLORIA trial. https://t.co/kNxwYMf59m https://t.co/rzRsZymlz3

Links:

Dr. John Cush RheumNow ( View Tweet)
RA: MACE Events with Opioids vs. NSAIDs The authors of abstract 1646 assessed MACE (myocardial infarction, stroke, heart failure, CVD death, VTE) and all-cause mortality in new users of opioids vs. matched NSAIDs new users. https://t.co/huz6NyYRlh https://t.co/dNYu7ybFZ5

Links:

Dr. John Cush RheumNow ( View Tweet)
Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence. Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis https://t.co/e5VCOC56BC https://t.co/vfuVWMrqSj

Links:

Dr. John Cush RheumNow ( View Tweet)
Netherlands study of 220 consecutive inflammatory arthritis pts enrolled in electronic remote telehealth monitoring showed that 141 (64%) dropped out, with a median dropout at 17 wks ( moreso in women). Why? Simple is not alway simple... https://t.co/nziKil4vas https://t.co/oyyulMnIu1

Links:

Dr. John Cush RheumNow ( View Tweet)
Sparks editorial -- RA pathogenesis has been linked to pollution, Lung Dz, smoking, silica dust, asbestos, textile dust, brick/concrete laying, pesticides, military burn pits - some w/ strong associ w/ HLA-SE and ACPA, but not ACPA-negative RA https://t.co/ZStmF8MeLD https://t.co/xQxJ74aQ81

Links:

Dr. John Cush RheumNow ( View Tweet)
cancer search news magnify

Xeljanz Cancer Risks Detailed

d MedPage Today

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Read Article
Tapering Methotrexate with Biologics or JAK Inhibitors in RA Dr Segan ( @JulianSegan) discusses Abstract 0916 at #ACR22. https://t.co/CUjZ7SiSoE https://t.co/VYtmCIJEt6

Links:

Dr. John Cush RheumNow ( View Tweet)
Why treatment of pre-RA isn't ready for prime time The ACR Great Debate was on "To treat or not to treat in pre-RA?" and it was stressed that autoimmunity may start well before clinical symptoms occur. https://t.co/A0dx3PFyiJ https://t.co/wqBuM8XD7M

Links:

Dr. John Cush RheumNow ( View Tweet)
cardiac2.jpg (keep)

TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis

d Jack Cush, MD

A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).

Read Article
cost.price_.biologic.injectable.jpg

Comparing Biosimilar Growth in the US, Germany, and Switzerland

d Jack Cush, MD

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.

Read Article
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx

Links:

Dr. John Cush RheumNow ( View Tweet)
Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/z3RTFt1hPb https://t.co/7rGn41qeu9

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.